Evidence map›Paper›PMID 41312791›Full record

ArticleAdvanced healthcare materials2026

Bioengineered Pancreatic Cancer Immunosuppressive Microenvironment Models for Screening Immunotherapies.

Maria V Monteiro, Margarida Henriques-Pereira, Bruno M Neves, Vítor M Gaspar, João F Mano

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maria V MonteiroDepartment of Chemistry, CICECO - Aveiro Institute of Materials, University of Aveiro, Campus Universitário de Santiago, Aveiro, Portugal.
Margarida Henriques-PereiraDepartment of Chemistry, CICECO - Aveiro Institute of Materials, University of Aveiro, Campus Universitário de Santiago, Aveiro, Portugal.
Bruno M NevesDepartment of Medical Sciences and Institute of Biomedicine - iBiMED, University of Aveiro, Aveiro, Portugal.
Vítor M GasparDepartment of Chemistry, CICECO - Aveiro Institute of Materials, University of Aveiro, Campus Universitário de Santiago, Aveiro, Portugal.ORCID 0000-0002-0372-2493
João F ManoDepartment of Chemistry, CICECO - Aveiro Institute of Materials, University of Aveiro, Campus Universitário de Santiago, Aveiro, Portugal.ORCID 0000-0002-2342-3765

Funding

PIDDACPortuguese Foundation for Science and Technology (FCT) 2023.03103.BDANA MHPPortuguese Foundation for Science and Technology (FCT) DFA/BD/7692/2020 MVMPrograma Operacional Competitividade e Internacionalização (POCI)
6 · The paper itself

Abstract

Pancreatic cancer is notably resistant to treatment, primarily due to its dense desmoplastic stroma and immunosuppressive microenvironment. Accurately modeling this complex landscape and its immunosuppressive hallmarks in vitro is highly valuable for screening immunotherapeutic strategies. However, replicating these intricate features remains a significant challenge. Herein, we bioengineered miniaturized tumor-stroma platforms that combine cancer and stromal cells, as well as extracellular matrix mimetic biomaterials as a strategy to emulate the native tumor composition and key tumor immunosuppressive signatures. Bioengineered stratified tumor-stroma pancreatic cancer models, so termed cancer-on-a-bead platforms are generated in superhydrophobic surfaces and co-cultured with T cells, dendritic cells, as well as M0 macrophages, as a strategy to recapitulate tumor-immune interplay. The generated models revealed suppression of antigen presentation, M2 macrophage polarization, and T cell exhaustion, representing key features of this neoplasia. The screening of antibody mediated immunotherapy in the 3D tumor platforms, using clinically approved anti PD-1 antibody as a model therapeutic, partially restored T cell function. Overall, our findings demonstrate compartmentalized tumor-stroma models potential for being used to screen candidate immunotherapeutics for pancreatic cancer in a preclinical setting.

Indexed as

BioengineeringImmunotherapyPancreatic NeoplasmsTumor MicroenvironmentAnimalsCell Line, TumorCoculture TechniquesHumansMacrophagesT-Lymphocytesimmunosuppressive microenvironmentimmunotherapyin vitro modelspancreatic cancertumor‐stroma interactions

Identifiers

PMID41312791
PMCPMC12927528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.